The effort has been hit by the dramatic coronavirus surge in India. Covax is heavily reliant on the Oxford-AstraZeneca vaccine, particularly doses manufactured by India’s Serum Institute. As India’s coronavirus death toll has climbed, exports have all but ceased. Covax knows it needs to diversify its vaccine portfolio, but the limited supply of messenger RNA vaccines and temporary halts on the use of other vaccines have made that tough.

Source: Washington Post May 03, 2021 15:36 UTC